A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-29. Anything still debated is marked as such rather than presented as settled.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
A few psychiatrists (including Sakel) claimed success rates for insulin coma therapy of over 80% in the treatment of schizophrenia. A few others argued that it merely accelerated remission in those patients who were undergoing remission anyway. The consensus at the time was somewhere in between, claiming a success rate of about 50% in patients who had been ill for less than a year (about double the spontaneous remission rate) with no influence on relapse. Sakel suggested the therapy worked by "causing an intensification of the tonus of the parasympathetic end of the autonomic nervous system, by blockading the nerve cell, and by strengthening the anabolic force which induces the restoration of the normal function of the nerve cell and the recovery of the patient." The shock therapies in general had developed on the erroneous premise that epilepsy and schizophrenia rarely occurred in the same patient. The premise was supported by neuropathologic studies that found a dearth of glia in the brains of schizophrenic patients and a surplus of glia in epileptic brains. These observations led the Hungarian neuropsychiatrist Ladislas Meduna to induce seizures in schizophrenic patients with injections of camphor, soon replaced by pentylenetetrazol (Metrazole). Another theory was that patients were somehow "jolted" out of their mental illness. The hypoglycemia (pathologically low glucose levels) that resulted from insulin coma therapy made patients extremely restless, sweaty, and liable to further convulsions and "after-shocks".
=== Contestants === 1st - Michelle Antonishek, Executive Pastry Chef from Cotulla, Texas 2nd - Tamara Brown, Home Baker from Baldwin Park, California 3rd - Veronica von Borstel, Cake Designer from San Diego, California 4th - John Schopp, Pastry Instructor from Roanoke, Virginia 5th - Amy Strickland, Bakery Owner from Lake City, Florida1 6th - Damien Bagley, Pastry Instructor from Las Vegas, Nevada 7th - Brad Rudd, Bakery Manager from Encino, California ^Note 1: Amy Strickland withdrew from the competition, just before the start of the third episode, due to stress concerns since she was 6 months pregnant.
== Early life == Elizabeth Evans Hughes was born August 19, 1907, in the New York State Executive Mansion in Albany, New York, to Antoinette (Carter) and Charles Evans Hughes, who was Governor of New York at the time. Elizabeth developed diabetes in 1918 at age 11. At the time, the life expectancy of a Type 1 diabetic without treatment was usually no more than a few months. Since it was unable to metabolize sugars, the diabetic body would instead begin to burn fats. The dependence on fat would eventually lead to acidosis, followed by coma and death. The only known treatment was a low-carbohydrate low-calorie diet at a level that the patient could tolerate without showing sugar in the urine. If the diet was carefully observed, diabetics could expect to live for a couple of years before eventually succumbing to starvation, organ damage, or an infectious disease in their malnourished state. In spring 1919, Elizabeth Hughes was brought to Dr. Frederick Madison Allen at his special clinic, the Physiatric Institute in Morristown, New Jersey. Allen put her on a strict diet and continued to monitor her condition over the next three years while she lived at home with a private nurse. She was 4 feet 11.5 inches (1.511 m) and 75 pounds (34 kg) when she developed diabetes. Under diets that averaged 800 calories per day, her weight fell to 45 pounds (20 kg) by August 1922.
== Student body and campus == As of 2025, Einstein had 789 medical students according to U.S. News & World Report. Admission to Einstein's MD program is highly selective, with an acceptance rate of 1.85% in 2024. All students are awarded the full-tuition Gottesman Scholarship. The average post-scholarship cost of attendance for all four years is $138,000. New York residents comprise 44 percent of MD students. Einstein offers housing for students and postdoctoral researchers. Student housing consists of three 28-story towers built in 1970. Living spaces include studios, three-bedroom penthouses, and one-, two-, or three-bedroom apartments. The campus also hosts a recreational facility, the Falk Center, that houses a gym, pool, and courts for basketball, racquetball, and squash. An underground parking garage is located on campus.
=== Environmental and health concerns === Fluoroalkenes and fluorinated alkynes are reactive and many are toxic for example perfluoroisobutene. To produce polytetrafluoroethylene various fluorinated surfactants are used, in the process known as Emulsion polymerization, and the surfactant included in the polymer can bioaccumulate.
Sources: en.wikipedia.org
== Synthesis == The synthesis of metal carbonyls is a widely studied subject of organometallic research. Since the work of Mond and then Hieber, many procedures have been developed for the preparation of mononuclear metal carbonyls as well as homo- and heterometallic carbonyl clusters.
== Interactions == The risk of bradycardia is increased if used with amiodarone, digoxin, diltiazem, ivabradine, or verapamil. Also, combination of carvedilol with non-dihydropyridine calcium channel blockers, including diltiazem and verapamil, enhances it cardiodepressant effects.
=== Available forms === Suvorexant is available in the form of 5, 10, 15, and 20 mg oral film-coated tablets. It is provided as 10- and 30-tablet blister packs as well as 3-tablet starter packs. The availability of these different packs varies by country.
== Background == He received his medical degree in 1982 from the National Autonomous University of Mexico. After postdoctoral training at University of California, San Diego (UCSD) he became a tenure-track professor at UCSD's Department of Neuroscience, with a joint appointment in Pathology. He also directed the neuropathology core of the Shirley-Marcos Alzheimer's Disease Research Center at UCSD. He was appointed head of the U.S. National Institute on Aging's Division of Neuroscience in 2016. He has a prolific body of work — over 800 research papers, much of which is now under scrutiny for containing manipulated images to support different conclusions than the real data. In September 2024, the NIH released a statement that stated he was no longer serving in the role of Director of the Division of Neuroscience.
Sources: en.wikipedia.org
== In-house writers == Tania Carmenatti, Dana Meyers, Dennis "Den Den" Nelson, Dynasty members Nidra Beard & William Shelby, The Time member Ricky Darnell "Freeze" Smith, The Sylvers member Charmaine Sylvers, and Johnny Thomas Jr. were frequent writing collaborators on various SOLAR albums and/or for various SOLAR acts. Credits are courtesy of Tidal and Spotify. (A majority of Beard and Shelby's written contributions to their own group are omitted)
== History == Experimentally the first examples of mechanically interlocked molecular architectures appeared in the 1960s with catenanes being synthesized by Wasserman and Schill and rotaxanes by Harrison and Harrison. The chemistry of MIMAs came of age when Sauvage pioneered their synthesis using templating methods. In the early 1990s the usefulness and even the existence of MIMAs were challenged. The latter concern was addressed by X ray crystallographer and structural chemist David Williams. Two postdoctoral researchers who took on the challenge of producing [5]catenane (olympiadane) pushed the boundaries of the complexity of MIMAs that could be synthesized their success was confirmed in 1996 by a solid‐state structure analysis conducted by David Williams.
Second, Downstream-peptides are consistently positioned in a place that is consistent with a cis-regulatory role in regulating the downstream ORFs, although the biological role of the ORFs is unknown. Third, the pseudoknot structure has a moderate complexity that is typical of riboswitches. Finally, the observation of regulation of a downstream ORF by nitrogen availability also suggests a cis-regulatory role of the element. This hypothesis is supported by biochemical and genetic data. First, both Downstream-peptide RNAs and glnA RNAs selectively bind glutamine. Second, reporter gene analysis of the Downstream-peptide motif revealed that this RNA promotes reporter gene expression upon binding of glutamine and can therefore be considered an activating riboswitch. Possible candidates to be regulated by the Downstream-peptide motif are genes that frequently carry the Downstream-peptide motif in their 5′UTR and encode small, unknown proteins that contain DUF4278 and are putative regulators of glutamine synthetase. This hypothesis is supported by the finding that expression of the DUF4278-containing glutamine synthetase inhibitory factor IF17 encoding gene gifB was shown to be regulated by the structurally related glnA RNA motif. Downstream-peptide RNAs overlap a predicted non-coding RNA called yfr6 that is over 200 nucleotides in length, but it was proposed that only the upstream region (corresponding to the Downstream-peptide motif) functions as an RNA structure. A distinct predicted non-coding RNA called yfr14 overlaps both yfr6 and Downstream-peptide RNAs.
The morphological structure of the human breast is identical in males and females until puberty. For pubescent girls in thelarche (the breast-development stage), the female sex hormones (principally estrogens) in conjunction with growth hormone promote the sprouting, growth, and development of the breasts. During this time, the mammary glands grow in size and volume and begin resting on the chest. These development stages of secondary sex characteristics (breasts, pubic hair, etc.) are illustrated in the five-stage Tanner scale. During thelarche, the developing breasts are sometimes of unequal size, and usually the left breast is slightly larger. This condition of asymmetry is transitory and statistically normal in female physical and sexual development. Medical conditions can cause overdevelopment (e.g., juvenile breast hypertrophy, macromastia) or underdevelopment (e.g., tuberous breast deformity, micromastia) in girls and women. Approximately two years after the onset of puberty (a girl's first menstrual cycle), estrogen and growth hormone stimulate the development and growth of the glandular fat and suspensory tissues that compose the breast. This continues for approximately four years until the final shape of the breast (size, volume, density) is established at about the age of 21. Mammoplasia (breast enlargement) in girls begins at puberty, unlike all other primates, in which breasts enlarge only during lactation.
== Purification process == Water is typically sourced from city feed water or other local supplies and is taken through a series of purification steps that results in UPW. Some systems recycle used UPW water back into their UPW filtration system as this water is often cleaner than original sources. The purification steps have been broadly categorized into pretreatment, primary treatment, polishing, and/or distribution. These are not strict categories, and certain purification techniques may be present in one or more of the broader steps depending on specific engineering needs or author classification.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.